Loading
A phase 3 trial of Isatuximab, Lenalidomide and Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma is a phase 3 interventional study registered as NCT04270409 by Sanofi, with 337 participants enrolled, started 2020-06-16 and due to reach its primary completion in 2030-10-14. Interventions recorded: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen and Diphenhydramine or equivalent.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies and the tag pipeline.
Shares Sanofi, Multiple myeloma and the tag pipeline.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies and the tag pipeline.
Shares Smouldering multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/